• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组组织型纤溶酶原激活剂与尿激酶用于股腘动脉闭塞局部溶栓的比较:一项前瞻性、随机多中心试验。

Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: a prospective, randomized multicenter trial.

作者信息

Mahler F, Schneider E, Hess H

机构信息

University Hospital of Bern, Switzerland.

出版信息

J Endovasc Ther. 2001 Dec;8(6):638-47. doi: 10.1177/152660280100800618.

DOI:10.1177/152660280100800618
PMID:11797982
Abstract

PURPOSE

To report the outcome of a prospective, randomized, open multicenter trial comparing (1) the effects of local thrombolysis with recombinant tissue plasminogen activator (rtPA) or urokinase (UK) and (2) 2 administration techniques.

METHODS

Two hundred thirty-four patients with thromboembolic occlusions in 223 native femoral or popliteal arteries (95%) and 11 bypass grafts (5%) were randomized to rtPA (n = 124) or UK (n = 110) administered either through an endhole catheter (Hess technique) in 81 patients or a microporous balloon catheter (Schneider technique) in 153 patients. When lysis was incomplete, additional catheter interventions were applied to achieve patency. Results were analyzed by fluoroscopy during intervention and by angiography evaluated by independent experts blinded to the methods applied.

RESULTS

The only significant difference between rtPA and UK was found at the end of lysis using the Hess technique. Complete reperfusion (TIMI grade 3) was produced in 60% of patients by rtPA versus 37% by UK (p = 0.045). By both techniques TIMI grade 3 was achieved in 62% with rtPA and in 50% with UK (p = 0.18). Independent of delivery technique, thrombolytic agent, or additional catheter interventions, TIMI grade 3 was achieved in 81% and angiographic patency in 88%. Primary patency at 6 months was 66%, which was increased by secondary interventions to 75%. Major amputations were performed in 6%, all in patients with initial Fontaine stage III/IV ischemia.

CONCLUSIONS

With local thrombolysis alone, rtPA appears to be more effective than UK; however, additional catheter interventions further improved patency, abolishing the difference between the lytic agents.

摘要

目的

报告一项前瞻性、随机、开放的多中心试验结果,该试验比较了(1)重组组织型纤溶酶原激活剂(rtPA)或尿激酶(UK)局部溶栓的效果,以及(2)两种给药技术。

方法

234例血栓栓塞性闭塞患者,其中223例为原位股动脉或腘动脉(95%),11例为旁路移植血管(5%),随机分为rtPA组(n = 124)或UK组(n = 110),81例患者通过端孔导管(Hess技术)给药,153例患者通过微孔球囊导管(Schneider技术)给药。当溶栓不完全时,采用额外的导管干预措施以实现血管通畅。在干预过程中通过荧光透视进行结果分析,并由对所应用方法不知情的独立专家进行血管造影评估。

结果

rtPA和UK之间唯一的显著差异出现在使用Hess技术溶栓结束时。rtPA使60%的患者实现完全再灌注(TIMI 3级),而UK为37%(p = 0.045)。两种技术下,rtPA组62%的患者达到TIMI 3级,UK组为50%(p = 0.18)。无论给药技术、溶栓剂或额外的导管干预如何,81%的患者达到TIMI 3级,88%的患者血管造影显示通畅。6个月时的初始通畅率为66%,通过二次干预后提高到75%。6%的患者进行了大截肢,均为初始处于Fontaine III/IV期缺血的患者。

结论

仅局部溶栓时,rtPA似乎比UK更有效;然而,额外的导管干预进一步提高了通畅率,消除了溶栓剂之间的差异。

相似文献

1
Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: a prospective, randomized multicenter trial.重组组织型纤溶酶原激活剂与尿激酶用于股腘动脉闭塞局部溶栓的比较:一项前瞻性、随机多中心试验。
J Endovasc Ther. 2001 Dec;8(6):638-47. doi: 10.1177/152660280100800618.
2
When is urokinase treatment an effective sole or adjunctive treatment for acute limb ischemia secondary to native artery occlusion?对于由天然动脉闭塞继发的急性肢体缺血,尿激酶治疗何时是一种有效的单一或辅助治疗方法?
Am J Surg. 1999 Aug;178(2):103-6. doi: 10.1016/s0002-9610(99)00135-x.
3
Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity.非栓塞性下肢自体动脉闭塞的手术血管重建与溶栓治疗:一项前瞻性随机试验的结果。STILE研究组。下肢缺血的手术治疗与溶栓治疗。
J Vasc Surg. 1996 Oct;24(4):513-21; discussion 521-3. doi: 10.1016/s0741-5214(96)70067-8.
4
Safety of thrombolytic therapy with urokinase or recombinant tissue plasminogen activator for peripheral arterial occlusion: a comprehensive compilation of published work.尿激酶或重组组织型纤溶酶原激活剂溶栓治疗外周动脉闭塞的安全性:已发表研究的综合汇编
J Endovasc Ther. 2004 Aug;11(4):436-46. doi: 10.1583/04-1226.1.
5
Potential benefits from heating the high-dose rtPA boluses used in catheter-directed thrombolysis for acute/subacute lower limb ischemia.在导管定向溶栓治疗急性/亚急性下肢缺血中,加热高剂量重组组织型纤溶酶原激活剂(rtPA)推注剂量可能带来的益处。
J Endovasc Ther. 2003 Aug;10(4):739-44. doi: 10.1177/152660280301000409.
6
Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts.下肢搭桥移植血管闭塞的手术与溶栓前瞻性随机试验结果。
Am J Surg. 1996 Aug;172(2):105-12. doi: 10.1016/S0002-9610(96)00129-8.
7
Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry.导管定向溶栓治疗下肢深静脉血栓形成:一项全国多中心注册研究报告
Radiology. 1999 Apr;211(1):39-49. doi: 10.1148/radiology.211.1.r99ap4739.
8
Intraarterial catheter-directed thrombolysis: urokinase versus tissue plasminogen activator.动脉内导管定向溶栓:尿激酶与组织型纤溶酶原激活剂的比较
Ann Vasc Surg. 1999 Nov;13(6):571-5. doi: 10.1007/s100169900300.
9
[Local infiltration thrombolysis of arterial occlusions with tissue plasminogen activator].[组织型纤溶酶原激活剂对动脉闭塞进行局部浸润溶栓治疗]
Med Klin (Munich). 1992 Nov 15;87(11):563-6.
10
Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions.组织型纤溶酶原激活剂与尿激酶在外周动脉闭塞局部浸润溶栓中的比较。
Eur J Radiol. 1996 May;22(2):129-32. doi: 10.1016/0720-048x(96)00742-5.

引用本文的文献

1
Fibrinolytic agents for peripheral arterial occlusion.用于外周动脉闭塞的纤溶药物。
Cochrane Database Syst Rev. 2013 Dec 19;2013(12):CD001099. doi: 10.1002/14651858.CD001099.pub3.
2
Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.外周动脉疾病的抗血栓治疗:抗血栓治疗与血栓预防,第 9 版:美国胸科医师学会循证临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e669S-e690S. doi: 10.1378/chest.11-2307.
3
Risk factors for haemorrhage during local intra-arterial thrombolysis for lower limb ischaemia.
下肢缺血局部动脉内溶栓治疗出血的危险因素。
J Thromb Thrombolysis. 2011 Feb;31(2):226-32. doi: 10.1007/s11239-010-0520-2.
4
[Peripheral arterial disease. Diagnosis and therapy according to current guidelines].[外周动脉疾病。根据当前指南进行诊断和治疗]
Radiologe. 2008 Nov;48(11):1022-8, 1030-1. doi: 10.1007/s00117-008-1705-y.
5
Transhepatic fibrinolysis of mesenteric and portal vein thrombosis in a patient with ulcerative colitis: a case report.溃疡性结肠炎患者肠系膜和门静脉血栓形成的经肝纤维蛋白溶解术:一例报告
World J Gastroenterol. 2005 Apr 7;11(13):2035-8. doi: 10.3748/wjg.v11.i13.2035.
6
[Intra-arterial lysis therapy in acute limb ischemia. Technical possibilities and limits of indication].[急性肢体缺血的动脉内溶栓治疗。技术可能性及适应证限度]
Chirurg. 2003 Dec;74(12):1103-9. doi: 10.1007/s00104-003-0772-x.